Varicella vaccination in Italy and Germany - different routes to success: a systematic review.


Journal

Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 25 9 2020
medline: 1 4 2021
entrez: 24 9 2020
Statut: ppublish

Résumé

Italy (in pilot regions) and Germany (nationwide) were the first European countries to introduce universal varicella vaccination (UVV) programs. A systematic review was performed to assess varicella epidemiology before UVV programs and the impact of 1-dose and 2-dose UVV programs in Italy and Germany. Italy implemented 1- or 2-dose UVV programs successively in eight pilot regions between 2003 and 2011 and nationwide in 2017. Germany implemented 1- and 2-dose UVV programs in 2004 and 2009, respectively. While Italy had two nationwide surveillance systems in place for varicella in the pre-vaccination era, in Germany, a mandatory notification system for varicella was only introduced in the New Federal States 2 years before the 1-dose UVV implementation. Substantial reductions in moderate/severe varicella and varicella-related hospitalization incidence occurred during the 1-dose era. Further reductions were reported in Italy and Germany after the recommendation of a second dose in a long or short schedule, respectively. Different benefit-risk evaluations of a tetravalent varicella-containing vaccine (MMRV) used as a first dose led to different recommendations (MMRV versus MMR+V) in these countries. Vaccination strategies in both countries tailored to country-specific needs and goals led to a reduction in varicella-related health care hospitalization costs.

Identifiants

pubmed: 32969747
doi: 10.1080/14760584.2020.1825947
doi:

Substances chimiques

Chickenpox Vaccine 0
Measles-Mumps-Rubella Vaccine 0
Vaccines, Combined 0
measles, mumps, rubella, varicella vaccine 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

843-869

Auteurs

Florence Kauffmann (F)

GSK , Wavre, Belgium.

Angela Bechini (A)

Department of Health Sciences, University of Florence , Florence, Italy.

Paolo Bonanni (P)

Department of Health Sciences, University of Florence , Florence, Italy.

Giacomo Casabona (G)

GSK , Wavre, Belgium.

Peter Wutzler (P)

Section of Experimental Virology, Institute of Medical Microbiology, University-Hospital Jena , Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH